Treatment use
Received a benzodiazepine
88.3%
181 of 205 patients
US tertiary-care hospital, adults with catatonia · Selected hospital episodes, 2001–2021
Treatment use
Received electroconvulsive therapy (ECT)
9.1%
5,645 of 61,990 hospitalizations
US acute-care discharges with a catatonia diagnosis, all ages · 2016–2020
Acute outcomes
Catatonic signs resolved with lorazepam
70%
21 of 30 inpatients
Puducherry, India, prospective open trial · During a five-day trial
Acute outcomes
Clinical response after ECT
80.8%
21 of 26 patients
Pisa, Italy, bipolar disorder with benzodiazepine-resistant catatonia · End of the ECT course
Follow-up
Catatonia returned during follow-up
48.8%
148 of 303 patients
Bengaluru, India, people with a psychotic or mood disorder · Median follow-up 29.8 months
Clinical context
Schizophrenia in a catatonia-positive group
47.7%
21 of 44 screen-positive patients
One acute mental health unit in South Africa, ages 16 and older · Sept 2020–Aug 2021
Clinical context
Bipolar disorder in the same group
27.3%
12 of 44 screen-positive patients
One acute mental health unit in South Africa, ages 16 and older · Sept 2020–Aug 2021
Clinical context
Autism recorded with pediatric catatonia
15.8%
515 of 3,255 pediatric hospitalizations
US acute-care catatonia discharges, age 18 or younger · 2016–2020
Clinical context
Other encephalitis recorded
6.6%
215 of 3,255 pediatric hospitalizations
US acute-care catatonia discharges, age 18 or younger · 2016–2020
Clinical context
Catatonia across clinical samples
9%
110,764 clinical participants across 80 samples
74 studies of clinical populations in several countries · Data from 1935–2017